Dauvilliers, Yves
Schenck, Carlos H.
Postuma, Ronald B.
Iranzo, Alex
Luppi, Pierre-Herve
Plazzi, Giuseppe
Montplaisir, Jacques
Boeve, Bradley
Article History
First Online: 30 August 2018
Competing interests
: Y.D. has consulted for UCB Pharma, Jazz, Theranexus, Flamel, Idorsia, Takeda, Harmony Biosciences and Bioprojet. C.H.S. is a Consultant for Axovant Sciences, Inc. R.B.P. reports grants and personal fees from Fonds de la Recherche en Sante, the Canadian Institute of Health Research, Parkinson Canada, the Garfield Weston Foundation, the Michael J. Fox Foundation and the Webster Foundation and personal fees from Biotie, Roche/Prothena, Takeda, Teva Neurosciences, AbbVie, Novartis, Janssen, Jazz Pharmaceuticals, Biogen, Boehringer Ingelheim, Theranexus and GE HealthCare outside the submitted work. G.P. participated in advisory boards for Jazz Pharmaceuticals, UCB Pharma and Bioprojet. J.M. received an honorarium to participate in advisory boards for Merck, Novartis and Takeda pharmaceuticals. B.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant, receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017) and serves on the Scientific Advisory Board of the Tau Consortium. B.B. also receives research support from the NIH (U01 AG045390, U54 NS092089, P50 AG016574, UO1 AG006786 and RO1 AG041797), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. All other authors declare no competing interests.